Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Cemiplimab + ISA101b
Indication/Tumor Type oropharynx cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive oropharynx cancer predicted - sensitive Cemiplimab + ISA101b Phase II Actionable In a Phase II trial, ISA101b and Libtayo (cemiplimab) combination treatment demonstrated safety in patients with HPV16-positive oropharynx cancer and resulted in an overall response rate (ORR) that did not significantly differ from placebo plus Libtayo (cemiplimab) in the full analysis set (25.3 vs 22.9%, p=0.590), but in CD274 (PD-L1)-positive patients in the per protocol set (CPS>/=20), the ORR was significantly improved (61.9 vs 28.0%, p=0.026) (J Clin Oncol 42, 2024 (suppl 16; abstr 6003); NCT03669718). detail...
PubMed Id Reference Title Details
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC). Full reference...